// App-Quantinova.ai

: Safety, tolerability, pharmacokinetics and pharmacodynamics after repeated once or twice daily RVT-1201, a TPH inhibitor for treatment of PAH

Researchers

Presenter

  • Stephen Wring

Principal Investigators

  • Julie Rurka

  • Katelyn Crizer

  • Michelle Palacios

  • Michele Snyder

  • Laurence Keller

  • Philip Evans

  • David Carpenter

Medical Centers

  • Altavant Sciences, Durham, United States of America

  • Quotient Sciences Ltd, Nottingham, United Kingdom

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tryptophan Hydroxylase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Placebo Control

  • Pharmacokinetics

  • Pharmacodynamics

  • Single Center

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved